Navigation Links
Sequenom, Inc. Reports Financial Results For The First Quarter Of 2012
Date:5/3/2012

nd molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

About Sequenom Center for Molecular MedicineSequenom Center for Molecular Medicine (Sequenom CMM®) has two CAP accredited and CLIA-certified molecular diagnostics reference laboratories dedicated to the development and commercialization of laboratory developed tests for prenatal and retinal conditions and diseases.  Utilizing innovative proprietary technologies, Sequenom CMM provides test results that can be used as tools by clinicians in managing patient care.  Testing services are available only upon request to physicians.  Sequenom CMM works closely with key opinion leaders and experts in obstetrics, retinal care and genetics.  Sequenom CMM scientists use a variety of sophisticated and cutting-edge methodologies in the development and validation of tests.  Sequenom CMM is changing the landscape in genetic diagnostics. Visit http://www.scmmlab.com for more information on laboratory testing services.

SEQUENOM®, MaterniT21™ and MaterniT21™ PLUS are trademarks of Sequenom. All other trademarks and service marks are the property of their respective owners.

Forward-Looking Statements Except for the historical information contained herein, the matters set forth in this press release, including statements regarding recognition of diagnostic services revenue in the future and expect
'/>"/>

SOURCE Sequenom, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Sequenom, Inc. Announces Date of Third Quarter 2011 Financial Results and Conference Call
2. Neuland Labs Reports Financial Results For Fiscal Year 2012
3. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
4. GP Strategies Reports Strong First Quarter 2012 EPS of $0.23
5. Cardinal Health Reports Third-Quarter Results
6. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Neurocrine Biosciences Reports First Quarter 2012 Results
9. CVS Caremark Reports Record First Quarter Results
10. National Study: Teen "Heavy" Marijuana Use Up 80 Percent Since 2008, One in Ten Teens Reports Using Marijuana at Least 20 Times a Month
11. Thoratec Reports First Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... approval condition to the announced tender offer for all of the ... a result of the waiver, the transaction is no longer conditional ... on January 24, 2014 following the currently scheduled expiration time, subject ...
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of innovative medical-related ... their most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the ... the most litigious industry sectors of cases involving ...
(Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... REDWOOD CITY, Calif., March 19, 2012 Ingenuity Systems, ... life science researchers, today announced that the Weill Cornell ... iReport for use in its sequencing core facility.  Variant ... the output of whole genome and exome sequencing experiments ...
... 19, 2012  Johnson & Johnson (NYSE: JNJ) will provide ... parties on Monday, March 26th at approximately 10:30 ... College of Cardiology (ACC) Annual Scientific Sessions in ... of the EINSTEIN-PE study in treating patients with ...
Cached Medicine Technology:Weill Cornell Medical College Selects Ingenuity® Variant Analysis™ and Ingenuity® iReport™ for Sequencing Core Facility 2
(Date:4/18/2014)... Northwestern Medicine scientists could lead to potential new treatments ... with scleroderma. , Fibrosis, or scarring, is a ... skin and lungs can lead to serious organ damage ... new therapeutic options centers on findings made by Swati ... the role that a specific protein plays in promoting ...
(Date:4/17/2014)... Ill. One of the most popular vaccine brands ... And doctors may be overlooking some cost factors when ... a more expensive option, according to a new study ... vaccines to administer can be driven by numerous factors," ... and a professor of computer science and of mathematics ...
(Date:4/17/2014)... a review published in the April issue of ... Feinstein Institute for Medical Research, says it,s time to ... approach to treating sepsis, which kills millions worldwide ... occurs when molecules released into the bloodstream to fight ... Inflammation is necessary for maintaining good health without ...
(Date:4/17/2014)... as 10 million older Americans suffer from depression, often ... However, new research a project that followed the ... years found that Internet use among the elderly ... 30 percent. , "That,s a very strong effect," said ... information studies and media who led the project. "And ...
(Date:4/17/2014)... YORK April 17, 2014 EcoHealth Alliance, a ... health issues, published a comprehensive review today examining the ... Marburg virus. The review calls for improved global surveillance ... as the recent outbreak of Ebola in West Africa ... the countries of Guinea and Liberia. According to ...
Breaking Medicine News(10 mins):Health News:New clues on tissue scarring in scleroderma 2Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Internet use can help ward off depression among elderly 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3
... Current ,safe, levels of exposure set by CDC need to ... -- Children with blood lead levels well below those considered ... emotional development, British researchers report. , Currently, the maximum safe ... mcg/dl), which was set by the U.S. Centers for Disease ...
... ... professor at the University of Colorado Denver and Health Sciences Center, School of Business, ... healthcare communications company. , ... Knoxville, Tenn. (PRWEB) September 17, 2009 -- Michael Guthrie, MD, MBA, Executive in ...
... ... advisory board for PerfectServe, a healthcare communications company. , ... Knoxville, TN (PRWeb) Sept. 17, 2009 -- Alan ... company. The board provides guidance on innovative ways to leverage PerfectServe,s physician-contact network serving ...
... , , , ... with prescription drug coverage are more satisfied with their pharmacy ... those with wholly private insurance, according to the J.D. Power ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20050527/LAF028LOGO-a ) , , ...
... , PITTSBURGH, Sept. 17 ... solutions for individuals with speech, language and learning disabilities, today ... the Year award from Microsoft Corp. This award recognizes ... Microsoft software in their products. , , ...
... 17 Racial inequalities in health care access and quality ... health care costs over a four-year period according to a ... Economic Studies, a Washington-based think tank. , , ... University of Maryland found that over 30 percent of direct ...
Cached Medicine News:Health News:Even Small Amounts of Lead Harmful to Kids 2Health News:Even Small Amounts of Lead Harmful to Kids 3Health News:Dr. Michael Guthrie Named to PerfectServe Advisory Board 2Health News:Alan Weinstein Named Chairman of PerfectServe Advisory Board 2Health News:J.D. Power and Associates Reports: Among Pharmacy Customers, Satisfaction is Equally as High for the Privately Insured and for Those With Public-Private Insurance 2Health News:J.D. Power and Associates Reports: Among Pharmacy Customers, Satisfaction is Equally as High for the Privately Insured and for Those With Public-Private Insurance 3Health News:J.D. Power and Associates Reports: Among Pharmacy Customers, Satisfaction is Equally as High for the Privately Insured and for Those With Public-Private Insurance 4Health News:J.D. Power and Associates Reports: Among Pharmacy Customers, Satisfaction is Equally as High for the Privately Insured and for Those With Public-Private Insurance 5Health News:J.D. Power and Associates Reports: Among Pharmacy Customers, Satisfaction is Equally as High for the Privately Insured and for Those With Public-Private Insurance 6Health News:J.D. Power and Associates Reports: Among Pharmacy Customers, Satisfaction is Equally as High for the Privately Insured and for Those With Public-Private Insurance 7Health News:DynaVox Mayer-Johnson Receives Microsoft Award 2Health News:Study Finds Racial Inequalities Cost U.S. Health System Over $50 Billion a Year 2Health News:Study Finds Racial Inequalities Cost U.S. Health System Over $50 Billion a Year 3Health News:Study Finds Racial Inequalities Cost U.S. Health System Over $50 Billion a Year 4
Intended for the quantitative determination of triglycerides in serum or plasma. Reaction: endpoint. Wavelength: 520 nm. Linearity: 1000 mg/dL (11.3 mmol/L). Single vial, dry powder reagent....
Alkaline phosphatase FS (IFCC). For determination of alkaline phosphatase (ALP) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
Intended for the quantitative determination of alkaline phosphatase activity in serum or plasma. Kinetic reaction. 405 nm wavelength. 830 U/L at 30C linearity. Single vial, dry powder reagent....
For the direct quantitative determination of low density lipoprotein cholesterol (LDL-C) in human serum or plasma. For in vitro diagnostic use only....
Medicine Products: